TY - JOUR
T1 - p53 codon 72 polymorphism in bladder cancer - No evidence of association with increased risk or invasiveness
AU - Törüner, Gökçe A.
AU - Uçar, Ahmet
AU - Tez, Mesut
AU - Çetinkaya, Mesut
AU - Özen, Haluk
AU - Özçelik, Tayfun
N1 - Funding Information:
Acknowledgements The authors gratefully acknowledge grant support from the Turkish Scientific and Technical Research Association (TÜBÍTAK – SBAG 1948), Bilkent University, and patient sample contributions from Drs Mehmet Öztürk, and Isik G. Yulug. All experiments are performed in accordance with Turkish law and regulations.
PY - 2001
Y1 - 2001
N2 - We studied the effect of the p53 gene Arg72Pro polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients and 114 age-sex matched controls to determine whether this polymorphism is a biomarker for the risk and how aggressive the disease is. Genomic DNA was obtained from venous blood samples for genotype determination by PCR and restriction digestion. The genotype frequencies in the patient group were Arg/Arg: 0.3553, Arg/Pro: 0.4711, Pro/Pro: 0.1736, and in the control group Arg/Arg: 0.3684, Arg/Pro: 0.4825, Pro/Pro: 0.1491. The distribution of genotypes between the two groups was not statistically different (χ2 = 0.260, df: 2, P = 0.878). The patient group was subdivided into two groups as superficial bladder cancer (n = 88) and invasive bladder cancer (n = 33), according to the presence of muscle invasion. The distribution of genotypes in the superficial group was Arg/Arg: 0.3409, Arg/Pro: 0.5114, Pro/Pro: 0.1477 and in the invasive group Arg/Arg: 0.3940, Arg/Pro: 0.3636, Pro/Pro: 0.2424. No association was observed with the invasiveness of the tumor (χ2 = 2.542, df: 2, P = 0.281). Stratification of the data by tobacco exposure did not result in a significant difference in genotype frequencies. These data do not support an association between the p53 Arg72Pro polymorphism and bladder cancer.
AB - We studied the effect of the p53 gene Arg72Pro polymorphism on bladder cancer susceptibility in a case control study of 121 bladder cancer patients and 114 age-sex matched controls to determine whether this polymorphism is a biomarker for the risk and how aggressive the disease is. Genomic DNA was obtained from venous blood samples for genotype determination by PCR and restriction digestion. The genotype frequencies in the patient group were Arg/Arg: 0.3553, Arg/Pro: 0.4711, Pro/Pro: 0.1736, and in the control group Arg/Arg: 0.3684, Arg/Pro: 0.4825, Pro/Pro: 0.1491. The distribution of genotypes between the two groups was not statistically different (χ2 = 0.260, df: 2, P = 0.878). The patient group was subdivided into two groups as superficial bladder cancer (n = 88) and invasive bladder cancer (n = 33), according to the presence of muscle invasion. The distribution of genotypes in the superficial group was Arg/Arg: 0.3409, Arg/Pro: 0.5114, Pro/Pro: 0.1477 and in the invasive group Arg/Arg: 0.3940, Arg/Pro: 0.3636, Pro/Pro: 0.2424. No association was observed with the invasiveness of the tumor (χ2 = 2.542, df: 2, P = 0.281). Stratification of the data by tobacco exposure did not result in a significant difference in genotype frequencies. These data do not support an association between the p53 Arg72Pro polymorphism and bladder cancer.
KW - Bladder cancer
KW - Genetic susceptibility
KW - TP53 polymorphism
UR - http://www.scopus.com/inward/record.url?scp=0035674559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035674559&partnerID=8YFLogxK
U2 - 10.1007/s002400100218
DO - 10.1007/s002400100218
M3 - Article
C2 - 11828992
AN - SCOPUS:0035674559
SN - 0300-5623
VL - 29
SP - 393
EP - 395
JO - Urological Research
JF - Urological Research
IS - 6
ER -